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A B S T R A C T
Purpose
There is no consensus on the optimal systemic treatment of patients with extranodal marginal zone
lymphoma of mucosa-associated lymphoid tissue. The IELSG-19 phase III study, to our knowledge,
was the ﬁrst such study to address the question of ﬁrst-line treatment in a randomized trial.
Patients and Methods
Eligible patients were initially randomly assigned (1:1 ratio) to receive either chlorambucil mono-
therapy (6 mg/m2/d orally on weeks 1 to 6, 9 to 10, 13 to 14, 17 to 18, and 21 to 22) or a combination
of chlorambucil (same schedule as above) and rituximab (375 mg/m2 intravenously on day 1 of
weeks 1, 2, 3, 4, 9, 13, 17, and 21). After the planned enrollment of 252 patients, the protocol was
amended to continue with a three-arm design (1:1:6 ratio), with a new arm that included rituximab
alone (same schedule as the combination arm) andwith a ﬁnal sample size of 454 patients. Themain
end point was event-free survival (EFS). Analysis of chlorambucil versus the combination arm was
performed and reported separately before any analysis of the third arm.
Results
At a median follow-up of 7.4 years, addition of rituximab to chlorambucil led to signiﬁcantly better
EFS (hazard ratio, 0.54; 95% CI, 0.38 to 0.77). EFS at 5 years was 51% (95% CI, 42 to 60) with
chlorambucil alone, 50% (95% CI, 42 to 59) with rituximab alone, and 68% (95% CI, 60 to 76) with
the combination (P = .0009). Progression-free survival was also signiﬁcantly better with the
combination (P = .0119). Five-year overall survival was approximately 90% in each arm. All
treatments were well tolerated. No unexpected toxicities were recorded.
Conclusion
Rituximab in combination with chlorambucil demonstrated superior efﬁcacy in mucosa-associated
lymphoid tissue lymphoma; however, improvements in EFS and progression-free survival did not
translate into longer overall survival.
J Clin Oncol 35:1905-1912. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Extranodal marginal-zone B-cell lymphoma of
mucosa-associated lymphoid tissue (MALT
lymphoma) constitutes 8% of all non-Hodgkin
lymphomas.1,2
Apart from the eradication of Helicobacter
pylori as an initial treatment of early-stage gastric
MALT lymphoma,3 there is no consensus re-
garding optimal treatment of patients with gastric
involvement who experience failure with anti-
biotics who have extensive disease or primary
extragastric localization.1,4-7 Radiotherapy can re-
sult in long-term local control for localized lym-
phoma,8-10 but it is not always feasible. Up to one
third of patients present with disseminated disease
that involves multiple extranodal sites.11-14
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Few single agents or combination chemotherapy regimens
have been tested speciﬁcally in patients with MALT lymphomas,
and most of the available data come from small, phase II studies
with short follow-up that have generally tested compounds and
regimens used for treating other indolent lymphomas.15-17 Rit-
uximab has proven active in phase II studies18,19 and a study of
combined bendamustine and rituximab has shown promising
activity in ﬁrst-line treatment.20 More intensive combination
regimens are usually limited to patients with histologic trans-
formation or those with high tumor burden.2,21,22
The International Extranodal Lymphoma Study Group 19
(IELSG-19) study is the ﬁrst randomized trial to investigate systemic
treatment of MALT lymphoma. The study was initially designed to
compare chlorambucil alone and in combination with rituximab.
After the planned enrollment, the study protocol was amended to
add a third arm of treatment with rituximab alone.23 Preliminary
results of the ﬁrst two-arm portion of the study—rituximab plus
chlorambucil versus chlorambucil—were previously published.23
Here, we report the ﬁnal results of the entire three-arm study.
PATIENTS AND METHODS
Study Design
The IELSG-19 study, an open-label, randomized phase III trial, was
conducted at 78 centers in six countries according to the principles of the
Declaration of Helsinki and after approval by local institutional review
boards and/or ethics committees. All patients provided written informed
consent. The study was initially designed to randomly compare in a 1:1
ratio chlorambucil alone (arm A, standard treatment) with combination
chlorambucil plus rituximab (arm B, study treatment). After enrollment of
the planned 252 patients, the protocol was amended and continued with
a three-arm design. The new arm included rituximab alone (arm C, study
treatment), and the random assignment ratio was changed to 1:1:6 for
a ﬁnal total sample size of 454 patients. Following the amended protocol,
analysis of chlorambucil versus chlorambucil plus rituximab was per-
formed before any analysis of the third arm and reported previously.23
Random assignment was stratiﬁed by primary tumor site (gastric v
nongastric), nodal involvement (presence v absence), prior local therapy
(surgery, radiation, or antibiotics v nonpretreated), and International
Prognostic Index (IPI) score (low and low-intermediate risk v intermediate-
high and high risk).
Patient Population
Patients with MALT lymphoma—either newly diagnosed or those
who experienced relapse after prior local therapy—were eligible. Cen-
tral pathology review was performed. Patients with primary gastric
H. pylori–positive MALT lymphomas were eligible for inclusion in cases of
endoscopic and histologic evidence of disease progression at any time
post–H. pylori eradication or for stable disease with persistent lym-
phoma . 1 year after H. pylori eradication. Apart from H. pylori eradi-
cation, no prior systemic therapy was allowed. In all cases, measurable or
evaluable disease, according to the National Cancer Institute International
Workshop criteria,24 was required.
Treatments
Patients who were assigned to arm A received induction treatment
with daily chlorambucil of 6 mg/m2 orally for 42 consecutive days (weeks
1 to 6). After restaging, patients with stable disease or an objective
response then received chlorambucil 6 mg/m2 per day for 2 weeks every
4 weeks (one cycle) for up to four cycles (weeks 9 to 10, 13 to 14, 17 to 18,
and 21 to 22).
For patients who were assigned to arm B, chlorambucil was ad-
ministered as in arm A. Rituximab 375 mg/m2 was administered in-
travenously according tomanufacturer instructions on days 1, 8, 15, and 22
during the induction phase. After restaging, rituximab was administered
on day 1 of each of the subsequent chlorambucil cycles (weeks 9, 13, 17,
and 21). Patients in arm C received rituximab alone with the same schedule
used in arm B. Rituximab was provided by F Hoffmann-La Roche (Basel,
Switzerland).
Outcome Measures
Primary end point was event-free survival (EFS), calculated from the
date of trial registration to experience of treatment failure—including
disease progression, early discontinuation of protocol treatment for any reason,
or initiation of new treatment without documented progression—death
as a result of any cause, or last follow-up.24 Secondary end points were
complete response rate (CR), overall response rate (ORR), response du-
ration, progression-free survival (PFS), overall survival (OS), and toxicity.
Response was assessed after the ﬁrst 6 weeks of therapy and at the
end of treatment. Further assessments were scheduled every 4 months
for 2 years, every 6 months for the next 3 years, and then annually for at
least 5 years and included physical examination, routine laboratory
tests, chest x-ray, and abdominal ultrasound. Additional imaging and/
or endoscopic studies to evaluate all initial disease sites were planned as
appropriate.
Additional methodology details, including statistical analysis,
sample size calculation, and toxicity assessment, were previously
published.23
RESULTS
Patient Characteristics and Treatment
Figure 1 shows the patient ﬂow through the trial. Four
hundred ﬁfty-four patients were enrolled and randomly assigned:
151 to chlorambucil, 152 to chlorambucil plus rituximab, and 151
to rituximab. Forty-two patients—16 in arm A, 19 in B, and seven
in C—were shown to be ineligible and were excluded after pa-
thology review gave other diagnoses. Eleven additional patients
were not evaluable—six were never treated and ﬁve because of
major protocol violations. Therefore, the analyzed population
included 401 patients (131 in arm A, 132 in B, and 138 in C).
Baseline characteristics are listed in Table 1. With the exception of
a lower frequency of B symptoms in patients who were enrolled in
the chlorambucil arm, there were no signiﬁcant differences in the
distribution of known risk factors. Details on the distribution of
the anatomic sites across the three study arms are listed in Ap-
pendix Table A1 (online only).
Three hundred eighteen patients (79%) completed the
treatment program according to the protocol. Thirty-eight patients
required at least one chlorambucil dose reduction, but no ritux-
imab dose reduction was permitted. Treatment discontinuation
was recorded in 61 patients; 17 patients in arm B concomitantly
discontinued both drugs, 25 discontinued chlorambucil only (18
patients in arm A and seven in arm B), and 19 discontinued
rituximab only (three in arm B and 16 in arm C). This was usually
a result of toxicity, disease progression, or patient preference, and
withdrawal rates were not statistically different between arms.
Median duration of treatment with chlorambucil was 14 weeks in
arms A (range, 5 to 14 weeks) and B (range, 3 to 14 weeks). Median
number of delivered rituximab doses was eight in arms B and C
(range, 1 to 8 doses in both arms).
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Treatment
Five (1%) of 401 patients who were treated according to
protocol were never evaluated for response. One patient who
was assigned to arm B withdrew consent and was lost to follow-
up, one patient assigned to arm A experienced a fatal ische-
mic stroke during treatment, one patient in arm B died of
disease progression after histologic transformation during
treatment, and two patients in arm C withdrew after experi-
encing allergic reaction to the ﬁrst or second rituximab
administration.
Three hundred forty-ﬁve patients (86%; 95% CI, 82 to 89)
achieved an objective response, with 264 CR (66%) and 81
partial response (20%). Treatment with the combination of
chlorambucil plus rituximab produced better responses with
signiﬁcantly higher ORR and CR rates than either drug ad-
ministered alone. Results of response assessment—best re-
sponse according to treatment arm—are listed in Table 2.
Median time to best response was 3.8 months in the whole
cohort (interquartile range, 2.0 to 6.4 months) with no dif-
ference among the three arms (P = .367). There was a trend
toward longer remission duration in the combination arm, with
79% (95% CI, 71 to 85) of patients who achieved response in
continuous remission at 5 years compared with 70% (95% CI,
60 to 78) and 66% (95% CI, 56 to 74) in the chlorambucil and
rituximab arms, respectively; however, these differences did not
reach a statistical signiﬁcance (Fig 2).
Randomly assigned
      (N = 454)
* 11 patients were not evaluable: 7 never treated, 4 because of major protocol violations 
Analyzed
(n = 138)
Excluded
for revised
diagnosis
(n = 7)
ARM C
Rituximab
(n = 151)
Not
evaluable*
(n = 6) 
(n = 144)
Analyzed
(n = 131)
Excluded
for revised
diagnosis
(n = 16)
ARM A
Chlorambucil
(n = 151)
Not
evaluable*
(n = 4) 
(n = 135)
Analyzed
(n = 132)
Excluded
for revised
diagnosis
(n = 19)
ARM B
Rituximab+
Chlorambucil
(n = 152)
Not
evaluable*
(n = 1)
(n = 133)
Fig 1. CONSORT diagram of study proﬁle
and patient ﬂow. Forty-two patients were
excluded after revised diagnosis, had dif-
fuse large B-cell lymphoma (12 patients),
follicular lymphoma (four patients), mantle-
cell lymphoma (10 patients), primary splenic
marginal-zone B-cell lymphoma (nine pa-
tients), primary nodal marginal-zone B-cell
lymphoma (two patients), small lymphocytic
lymphoma (one patient), non–mucosa-as-
sociated lymphoid tissue (MALT) indolent
lymphoma, not otherwise classiﬁable (two
patients), and no evidence of lymphoma
tissue (two patients, one with chronic gas-
tritis and one with Crohn’s disease). (*)
Eleven patients were not evaluable: seven
were never treated and four had major
protocol violations.
Table 1. Baseline Patient Characteristics
Characteristic
All Patients
(N = 401)
Arm A Chlorambucil
(n = 131)
Arm B Chlorambucil
Plus Rituximab (n = 132)
Arm C Rituximab
(n = 138) P*
Median age (range), years 61 (26-81) 60 (26-80) 59.5 (26-79) 62.5 (27-81) .349
Male sex 197 (49.1) 69 (52.7) 64 (48.5) 64 (46.4) .578
Ann Arbor stage I 170 (42.4) 52 (39.7) 60 (45.4) 58 (42.0) .636
Ann Arbor stage III and IV 175 (43.6) 53 (40.6) 59 (44.7) 63 (45.6) .662
ECOG PS $ 2 6 (1.5) 4 (3.0) 1 (0.7) 1 (0.7) .293
Presence of B-symptoms 42 (10.5) 6 (4.6) 20 (15.1) 16 (11.6) .017
Elevated serum LDH (n = 400) 42 (10.5) 11 (8.5) 10 (7.6) 21 (15.3) .076
Extranodal sites $ 2 123 (30.7) 44 (33.6) 44 (33.3) 35 (25.4) .247
Nodal involvement 142 (35.4) 45 (34.3) 49 (37.2) 48 (34.8) .879
Bone marrow involvement 71 (17.7) 22 (16.8) 30 (22.7) 19 (13.8) .148
Prior local therapy† 32 (8.0) 14 (10.7) 10 (7.6) 8 (5.8) .328
Primary gastric site‡ 171 (42.6) 57 (43.5) 53 (40.1) 61 (44.2) .774
IPI risk (n = 400) .795
Low 229 (57.2) 79 (60.8) 74 (56.1) 76 (55.1)
Low-intermediate 94 (23.5) 25 (19.2) 34 (25.8) 35 (25.4)
Intermediate-high 68 (17.0) 23 (17.7) 20 (15.1) 25 (18.1)
High 9 (2.3) 3 (2.3) 4 (3.0) 2 (1.4)
NOTE. Data are given as No. (%) unless otherwise indicated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PS, performance status.
*P values refer to comparison of frequencies (x2 or Fisher’s exact test as appropriate) or medians (nonparametric k-sample test) in the three arms.
†Includes previous surgery, antibiotic therapy, and/or radiation therapy.
‡Includes 10 patients with other extranodal localizations.
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Time-Related End Point Analysis
Median follow-up of the entire study cohort (N = 401) was 7.4
years (interquartile range, 5.6 to 9.7 years) and, as a result of the
later addition of the third arm, it was longer in arms A and B (9.3
years; interquartile range, 6.8 to 10.3 years) than in arm C (5.7
years; interquartile range, 4.8 to 6.5 years).
Median EFS, the main end point of the study, was 8.6 years in
the whole cohort, but was signiﬁcantly shorter for patients who
were treated with chlorambucil alone (5.1 years) or with rituximab
alone (5.6 years) compared with those who received rituximab plus
chlorambucil (median EFS not reached; P = .0009). Compared
with chlorambucil alone, addition of rituximab resulted in sig-
niﬁcant reduction of the risk of EFS events (hazard ratio [HR],
0.54; 95% CI, 0.38 to 0.77), whereas rituximab alone showed
a nearly identical risk (HR, 0.97; 95% CI, 0.69 to 1.35). The 5-year
EFS in patients who were treated with combination therapy was
68% (95% CI, 60 to 76), 51% in those who received chlorambucil
alone (95% CI, 42 to 60), and 50% in those who were treated with
rituximab alone (95% CI, 42 to 59; Fig 3A).
Median PFS was signiﬁcantly better (P = .0119) in patients
who were treated with combination therapy: median not reached
versus 8.3 years and 6.9 years for chlorambucil and rituximab
alone, respectively. HR for the combination armwas 0.62 (95% CI,
0.42 to 0.93), whereas rituximab alone produced an outcome (HR,
1.10; 95% CI, 0.76 to 1.59) that was similar to chlorambucil alone
(Fig 3B). The 5-year PFS in patients who were treated with
combination therapy was also superior (72%; 95% CI, 63 to 79) to
that after chlorambucil (59%; 95% CI, 50 to 68) or rituximab
(57%; 95% CI, 48 to 65).
Overall, 58 patients—20 in arm A, 25 in arm B, and 13 in arm
C—have died. Causes of death are described in Table 3. There was
no signiﬁcant difference in OS (P = .464) between treatment arms
(Fig 3C). The 5-year OS rate was 90% (95% CI, 83 to 94) in
patients who were treated with combination therapy, 89% after
chlorambucil alone (95% CI, 82 to 93), and 92% after rituximab
(95% CI, 86 to 96).
Histologic transformation during the trial was reported in 10
patients (two in arm A, six in arm B, and two in arm C), and six
have died (four of six patients as a result of disease progression of
aggressive lymphoma). Second primary malignancies were re-
ported in 34 patients (14 in arm A, nine in arm B, and 11 in arm C;
P = .512): 27 solid tumors, four second B-cell neoplasms (one
acute lymphoblastic leukemia, one chronic lymphocytic leukemia,
and one mantle cell lymphoma), and three myeloid neoplasms.
Impact of Patient Characteristics on Outcome
In univariate analysis, IPI score and the presence of lymph
node involvement demonstrated a statistically signiﬁcant effect on
EFS, PFS, and OS in the whole cohort, whereas primary gastric
origin had an impact only on EFS and PFS. Conversely, there was
no impact for prior local treatment (Appendix Table A2, online
only). In multivariate analysis of EFS and PFS (Cox proportional
hazards regression model that included treatment in arm B and the
stratiﬁcation factors that had statistical signiﬁcance at univariate
analysis), the type of treatment remained signiﬁcantly associated
with EFS and PFS after controlling for nodal involvement, IPI group,
and primary site (Appendix Table A3, online only). In a similar Cox
proportional hazards regression model for OS—excluding primary
anatomic site—only the IPI group retained a signiﬁcant impact
(Appendix Table A3).
In addition to better EFS and PFS, the CR rate was also
signiﬁcantly (P = .015) higher in gastric (72%; 95% CI, 65 to 79)
versus primary nongastric lymphomas (61%; 95% CI, 54 to 67);
however, the gastric lymphoma group had a signiﬁcantly higher
rate of patients with localized disease (stage I disease in 60% v 30%;
P , .001), whereas the nongastric group comprised a variety of
Table 2. Response to Treatment
Response
All Patients
(N = 401)
Arm A
Chlorambucil (n = 131)
Arm B
Chlorambucil Plus Rituximab
(n = 132)
Arm C
Rituximab (n = 138)
No. % (95% CI) No. % (95% CI) No. % (95% CI) No. % (95% CI)
Complete remission* 264 65.8 (61.0 to 70.5) 83 63.4 (54.5 to 71.6) 104 78.8 (70.1 to 85.4) 77 55.8 (47.0 to 64.2)
Partial remission 81 20.2 (16.4 to 24.5) 29 22.1 (15.3 to 30.2) 21 15.9 (10.1 to 23.3) 31 22.5 (15.8 to 30.3)
Stable disease 28 7.0 (4.7 to 9.9) 11 8.4 (4.3 to 14.5) 1 0.8 (0.02 to 4.1) 16 11.6 (6.8 to 18.1)
Progressive disease 23 5.7 (3.7 to 8.5) 7 5.3 (2.2 to 10.7) 4 3.0 (0.8 to 7.6) 12 8.7 (3.0 to 12.0)
Not assessed 5 1.3 (0.4 to 2.9) 1 0.8 (0.02 to 4.2) 2 1.5 (0.2 to 5.4) 2 1.5 (0.2 to 5.1)
Overall response rate * 345 86.0 (82.2 to 89.3) 112 85.5 (78.3 to 91.0) 125 94.7 (89.4 to 97.8) 108 78.3 (70.4 to 84.8)
*P , .001.
Log-rank test, P = .071
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Fig 2. Kaplan-Meier estimates of response duration (RD) according to treatment
arm in the 345 patients who achieved a response (partial response, n = 81;
complete response, n = 264). HR, hazard ratio.
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anatomic primary localizations (Appendix Table A1) with diverse
outcomes (Appendix Fig A1, online only). Nevertheless, a signif-
icantly higher CR rate was achieved with combination therapy in
both primary gastric (91% v 61% after chlorambucil and 67% after
rituximab; P = .001) and primary nongastric MALT lymphomas
(72% v 62% after chlorambucil and 48% after rituximab; P = .008).
Log-rank test, P = .0009
Arm A (chlorambucil)
Arm B (R-chlorambucil)
Arm C (rituximab)
138 87 69 30 2 0 0
132 109 93 76 58 23 0
131 85 68 53 41 16 0
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138 90 71 31 2 0 0
132 110 94 77 59 23 0
131 89 70 53 42 16 0
HR, 1.00
HR, 0.54 (95% CI, 0.38 to 0.77)
HR, 0.97 (95% CI, 0.70 to 1.35)
HR, 1.00
HR, 1.24 (95% CI, 0.69 to 2.23)
HR, 0.91 (95% CI, 0.44 to 1.86)
HR, 1.00
HR, 0.62 (95% CI, 0.42 to 0.92)
HR, 1.10 (95% CI, 0.76 to 1.59)
C
Log-rank test, P = .62
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Fig 3. Kaplan-Meier survival curves according to treatment received for (A) event-free survival (EFS), (B) progression-free survival (PFS), and (C) overall survival (OS). HR,
hazard ratio.
Table 3. Causes of Death
Cause of Death
All Patients
(58 of 401; 14.5%)
Arm A
Chlorambucil (20 of 131; 15.3%)
Arm B
Chlorambucil Plus Rituximab
(25 of 132; 18.9%)
Arm C
Rituximab (13 of 138; 9.4%)*
Lymphoma progression 14 (24.1) 6 (30.0) 5 (20.0) 3 (23.1)
Second tumor 17 (29.3) 7 (35.0) 5 (20.0) 5 (38.4)
Transformed lymphoma 4 (6.9) 0 (0) 4 (16.0) 0 (0)
Infection 4 (6.9) 1 (5.0) 2 (8.0) 1 (7.7)
Respiratory failure 4 (6.9) 1 (5.0) 2 (8.0) 1 (7.7)
Stroke 4 (6.9) 1 (5.0) 1 (4.0) 2 (15.4)
Trauma 1 (1.72) 0 (0) 1 (4.0) 0 (0)
Deep venous thrombosis 1 (1.72) 1 (5.0) 0 (0) 0 (0)
Unknown 9 (15.5) 3 (15.0) 5 (20.0) 1 (7.7)
Total deaths 58 (100) 20 (34.5) 25 (43.1) 13 (22.4)
NOTE. Data are given as No. (%).
*The reduced death rate in arm C may simply reﬂect the signiﬁcantly shorter follow-up time and was not statistically signiﬁcant (P = .080)
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With respect to the primary end point of the study, a signif-
icantly longer EFS in patients who were treated with the combi-
nation of rituximab and chlorambucil was evident in both gastric
(P = .002) and nongastric (P = .022) patients as well as in those
with (P = .0054) or without (P = .0094) lymph node involvement
and those with low and low-intermediate IPI (P = .0005) but not in
those with unfavorable IPI scores (Appendix Table A4, online
only). As expected, patients with stage I disease had signiﬁcantly
better treatment outcome (Appendix Table A5, online only).
Safety
The safety population comprised all 401 patients whowere treated
according to protocol. Hematologic toxicity, as expected, was more
frequent in the combination arm (Table 4); however, all treatments
were well tolerated. A low number of adverse events was reported, with
no unexpected differences between treatment arms. Nonhematologic
adverse effects that occurred inmore than ﬁve patients are also listed in
Table 4, and a complete list of recorded nonhematologic toxicities is
given in Appendix Table A6 (online only).
DISCUSSION
This study is the ﬁnal report of the ﬁrst randomized trial on the
systemic treatment of MALT lymphoma. In a previous article, we
reported the initial results of patients who were randomly assigned
between chlorambucil and chlorambucil plus rituximab. The
present analysis concerns the ﬁnal results of the entire study
population and includes the third study arm (rituximab alone). At
the time of conception, chlorambucil alone was considered an
acceptable comparator arm for a study that was aimed at evaluating
the clinical beneﬁt of adding rituximab to chemotherapy.15 Al-
though rituximab as single agent was known to carry signiﬁ-
cant antitumor activity in MALT lymphomas,18 the efﬁcacy of
chemoimmunotherapy had never been formally tested in this
disease.
Sample size was calculated on a 20% difference in EFS, as-
suming that OS would likely not be affected in an indolent disease
and that the required beneﬁt in terms of EFS must be substantial to
justify the additional cost that is associated with use of rituximab.23
In this study, addition of rituximab to chlorambucil resulted
in improved remission quality—measured by ORR and CR
rate—and led to signiﬁcantly prolonged EFS and PFS. As expected,
differences in EFS, PFS, and response rate have not yet translated
into improved OS, likely as a result of effective second treatment
options in indolent disease (Appendix Tables A7-A8, online only).
Synergism in anticancer drug combinations can be formally
assessed only in preclinical studies; however, it is worth noting that
this is the only controlled clinical trial to date that compared
chemotherapy alone with the combination of rituximab and
chemotherapy or rituximab alone. With respect to the main study
end point, observed improvement in EFS (46% reduction in HR,
with 95% CI ranging from 23% to 62%) suggests that clinical
synergy of the drug combination may be present. This beneﬁt was
conﬁrmed in multivariate analysis of EFS and PFS, which also
showed that IPI and the presence of lymph node involvement are
associated with outcome (Appendix Table A3).
As the only randomized study that has speciﬁcally addressed
MALT lymphoma, these results can be considered a benchmark for
future trials in this entity. Lack of OS difference between arms has
also provided evidence for the use of rituximab alone as initial
therapy to delay or avoid the long-term risks of chemotherapy and
radiotherapy.
Table 4. Hematologic Toxicity and Nonhematologic Adverse Events Experienced by At Least Five Patients
Adverse Event
Arm A
Chlorambucil (n = 131)
Arm B
Chlorambucil Plus Rituximab (n = 132)
Arm C
Rituximab (n = 138)
G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4
Hematologic toxicity
Leukopenia 4 5 2 — 2 9 5 — — — 1 —
Neutropenia 3 3 — 2 4 3 10 9 — — 2 —
Lymphocytopenia — 2 2 — — 1 1 2 — — — —
Anemia 4 — 1 — 2 1 — — 1 — 0 —
Thrombocytopenia 2 3 1 — 2 2 2 — 1 — — —
Febrile neutropenia — — — — — — 3 — — — — —
Nonhematologic
Fatigue 12 4 — — 11 2 — — 12 4 — —
Fever 1 — — — 4 2 — — 5 3 — 1
Diarrhea 1 1 — — 5 1 — — 3 — — —
Dyspepsia 2 1 — — 2 — 3 — 1 — — —
Nausea 6 1 — — 17 1 — — 6 1 — —
Stomatitis 1 1 — — 3 — — — 1 — — —
Skin rash 5 2 — — 4 2 1 — 3 1 — —
Infections 3 11 2 1 1 8 4 — 4 6 4 —
Cough 2 — — — — — — — 4 2 — —
Transaminase increase — — 2 1 — 2 — 1 1 — 3 —
Gastric pain 6 2 1 — 6 4 1 — 3 4 — —
Headaches 2 — — — 2 2 — — 3 2 — —
IR symptoms — — — — 15 4 1 1 10 8 2 —
Abbreviations: G, toxicity grade (according to Common Terminology Criteria for Adverse Events version 3); IR, infusion related (including: bronchospasm, chills, fever,
rash, arthralgias, pruritus).
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In this study, patients with primary gastric localization,
a stratiﬁcation criterion, achieved better CR rate and EFS than did
those with nongastric lymphoma. The value of unplanned analysis
of patient subsets is debatable, and this ﬁnding does not necessarily
indicate that gastric MALT lymphoma represents a distinct disease.
The patients with gastric lymphoma who were enrolled in the
study, compared with those with extragastric localizations, had
a signiﬁcantly higher rate of stage I disease, which may explain the
different results. Moreover, extragastric sites comprise different
anatomic primary localizations that may have different clinical
outcomes, which has also been pointed out by a study of the SEER
database.25 The current study is underpowered to address the
clinical relevance of any individual anatomic localizations. Nev-
ertheless, the beneﬁt of combination therapy on the main study
end point—EFS—was statistically signiﬁcant in both gastric and
nongastric MALT lymphomas.
All treatments were well tolerated and no unexpected adverse
effects were recorded. To date, no clinically signiﬁcant differences
in acute and long-term toxicity have been observed between arms,
despite the expected occurrence of infusion-related symptoms in
the rituximab-containing arms, as well as increased the number of
patients with grade 3 and 4 neutropenia in the combination arm
(Table 4). This latter result did not cause a signiﬁcant increase in
neutropenic fever and infection rates.
A phase II study of the Spanish GELTAMO group has shown
promising activity with the combination of bendamustine and
rituximab for ﬁrst-line systemic treatment20 of MALT lymphoma.
This single-arm, phase II trial evaluated 57 patients. After
a median follow-up of 43 months, EFS at 4 years was 88% (95%
CI, 74 to 95). These results seemed to be extremely good, al-
though CIs overlap those of the IELSG-19 study. Moreover, in
arm B of the IELSG-19 trial, several unfavorable clinical features
were more common than in the GELTAMO study, including B
symptoms and involvement of multiple extranodal sites, lymph
nodes, and bone marrow. Hence, given the long natural history of
this disease and the different size and design of the studies, direct
comparison of these results with those of the randomized trial,
which has approximately three times longer follow up, should be
taken with caution.26
In conclusion, we have shown the superior efﬁcacy of rit-
uximab in combination with chlorambucil in treatment of MALT
lymphoma. Improved EFS and PFS with little added toxicity
justiﬁes the ﬁrst-line use of this regimen, and the results of this
controlled clinical study may deﬁne a standard regimen for
treatment of patients MALT lymphoma who are in need of sys-
temic therapy. The lack of OS beneﬁt, however, leaves room to
consider the use of chlorambucil alone when treatment cost is
a relevant issue, but also provides evidence for the use of single-
agent rituximab to avoid the toxicity of chemotherapy.
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15. Henri-Mondor Hospital, Paris Cre´teil, France (Corinne Haioun, Jean-Charles Delchier)
16. CHU Hoˆtel Dieu, Nantes, France (Be´atrice Mahe)
17. Clinical haematology, CHU Le Bocage Hospital, Dijon, France (Rene´ Olivier Casasnovas)
18. Haematology, CHU Nancy-Brabois, Nancy, France (Pierre Feugier)
19. Onco-haematology, Blois Hospital, Blois, France (Philippe Rodon)
20. Lens Hospital, Lens, France (Pierre Morel)
21. Haematology, Avicienne Hospital, Bobigny, France (Pierre Fenaux)
22. Arnaud de Villeneuve Hospital, Montpellier, France (Pascal Chanez)
23. Centre Rene´ Gaudiucheau, Nates-St Herblain, France (Annick Le Mevel)
24. Necker University Hospital, Paris, France (Olivier Hermine)
Italy
25. Division of Hematology, European Institute of Oncology, Milan, Italy (Giovanni Martinelli, Daniele Laszlo, Alberto Agazzi,
Fedro Peccatori, Emilia Cocorocchio, Pierfrancesco Ferrucci)
26. Haematology, Spedali Civili, Brescia, Italy (Giuseppe Rossi, Alessandra Tucci)
27. Haematology, University-Hospital Citta` della Salute e della Scienza, Turin, Italy (Umberto Vitolo, Lorella Orsucci, Barbara
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28. Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy (Maurizio Martelli)
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35. Haematology, G. B. Rossi Hospital, Verona, Italy (Roberta Zanotti)
36. Onco-Haematology, Guglielmo de Saliceto Hospital, Piacenza Hospital, Italy (Luigi Cavanna, Annalisa Arcari)
37. Santa Maria Nuova Hospital, Reggio Emilia, Italy (Fiorella Ilariucci)
38. Oncology, Azienda ULSS 15 “Alta Padovana” Camposampiero Hospital (Mariella Soraru`)
39. Oncology, Azienda ULSS 15 “Alta Padovana” Cittadella Hospital, Italy, (Alberto Morabito)
40. Oncology and Haematology, Humanitas Clinical Institute, Rozzano, Italy (Monica Balzarotti, Armando Santoro)
41. Haematology, S. Eugenio Hospital, Rome, Italy (Maria Christina Cox)
42. Ospedale Civile, Sassuolo, Italy (Giovanni Partesotti)
43. Haematology, Azienda ospedaliera, Siena, Italy (Francesco Lauria, Alberto Fabbri)
44. Oncologic DH, Correggio Hospital, Correggio, Italy (Alberto Bagnulo)
45. Oncology, Istituto Nazionale Ricerca Cancro, Genova, Italy (Mario Roberto Sertoli)
46. Haematology, S. Nicola Pellegrino Hospital, Trani, Italy (Giuseppe Tarantini)
Spain
47. Department of Haematology, Hospital Clinic, Barcelona, Spain (Emili Montserrat, Armando Lopez Guillermo)
48. Clinical Haematology, Santa Creu i Sant Pau Hospital, Barcelona, Spain (Javier Briones Meijide)
49. Hematology, Hospital Universitario, Salamanca, Spain (Dolores Caballero)
50. Haematology, Joan XXIII Hospital, Tarragon, Spain (Lourdes Escoda Teigell)
51. Haematology, Mataro´ Hospital, Barcelona, Spain (Jose´ Angel Herna´ndez, Lluı´s Rodriguez)
Switzerland
52. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland (Emanuele Zucca, Salvatore Grisanti, Luciano
Wannesson, Michele Ciriolo, Cristina Marini, Michele Ghielmini, Oreste Mora, Franco Cavalli)
United Kingdom
53. Haematology, St George’s University of London, London, United Kingdom (Ruth Pettengell)
54. Cancer research Center, Southampton General Hospital, Southampton, United Kingdom (Peter Johnson)
55. Medical Oncology, St. Bartholomew’s Hospital, London, United Kingdom (Sarah Payne, Silvia Montoto, Thomas A. Lister)
56. Haematology, Royal Inﬁrmary, Aberdeen, United Kingdom (Dominic Culligan)
57. Medical Oncology, Christie Hospital, Manchester, United Kingdom (John Radford)
58. Haematology, Royal Cornwall Hospital, Cornwall, United Kingdom (Anton Kruger)
59. Haematology, Nottingham City Hospital, Nottingham, United Kingdom (Andrew McMillan)
60. Haematology, Royal Devon and Exeter Hospital, Exeter, United Kingdom (Marylin Pocock, Claudius Rudin)
61. Haematology, Medway Maritime Hospital, Gillingham, United Kingdom (Maadh Aldouri)
62. Cancer Research Center, Weston Park Hospital, Shefﬁeld, United Kingdom (Barry William Hancock)
63. Worchestershire Acute Hospitals NHS Trust, Worcestershire, United Kingdom (Salim Shaffek)
64. Haematology, University Hospital Aintree, Liverpool, United Kingdom (Barrie Woodcok)
65. Haematology, Royal University Hospital, Liverpool, United Kingdom (Andrew Pettitt)
66. Haematology, The Royal Marsden Hospital, London, United Kingdom (David Cunningham)
67. Oncology, James Paget Hospital, Norfolk, United Kingdom (Shalal Sadullah)
68. Clinical Oncology, Birmingham Heartlands Hospital, Birmingham, United Kingdom (Donald Milligan)
69. Haematology, Victoria Hospital, Blackpool, United Kingdom (Mac Macheta)
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70. Clinical haematology and oncology, Russel Hall Hospital, Dudley, United Kingdom (Jeff Neilson)
71. Haematology, Western General Hospital, Edinburgh, United Kingdom (Mike J. Mackie, John M. Davies)
72. Clinical Oncology, Raigmore Hospital, Inverness, United Kingdom (Peter Forsyth)
73. Mount Vernon Hospital, Northwood, United Kingdom (Kirit M. Ardeshna)
74. Haematology, Queen Elisabeth Hospital, Norfolk, United Kingdom (Jane Keidan, Peter Coates)
75. Haematology, John Radcliffe Hospital, Oxford, United Kingdom (Chris Hatton)
76. Oncology, Conquest Hospital, St Leonards, United Kingdom (Simon Guy Weston Smith)
77. Sandwell and West Birmingham Hospitals, West Bromwich, United Kingdom (Penny Stableforth)
78. Darent Valley Hospital, Dartford, United Kingdom (Raphael Ezekwesili)
Pathology Expert Panel
The following pathologists contributed to the histology review committee:
Francoise Berger (Centre Hospitalier Lyon-Sud, Universite´ Claude Bernard, Lyon, France), Elias Campo (Pathology, Hospital
Clinic, Barcelona, Spain), Christiane Copie-Bergman (Pathology Department, Hoˆpital Henri Mondor, Paris Cre´teil Cedex, France),
Carlo Capella (Anatomia Patologica Universita` di Varese, Varese, Italy), Andrew Jack (Haematological Malignancy Diagnostic
Service, St James’s University Hospital, Leeds, United Kingdom), Luca Mazzucchelli (Istituto Cantonale di Patologia, Locarno,
Switzerland), Anne Moreau (Department of Histopathology, University Hospital of Nantes, Nantes, France), Marco Paulli
(Anatomia Patologica, Universita` di Pavia, Pavia, Italy), Stefano A. Pileri (Department of Hematology/Oncology, University of
Bologna, Bologna, Italy), Maurilio Ponzoni (San Raffaele Hospital, Milan, Italy).
Statistical Analysis
Statistical analysis was planned and supervised by Valter Torri (Pharmacological Research Institute, Milan, Italy) and Irene
Floriani (Pharmacological Research Institute, Milan, Italy). Luciano Cascione (Oncology Institute of Southern Switzerland,
Bellinzona, Switzerland) also contributed to the analysis.
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Fig A1. Kaplan-Meier event-free survival (EFS) curves by the primary localization of mucosa-associated lymphoid tissue (MALT) lymphoma in (A) gastric versus
extragastric disease and in (B) the most frequent primary extragastric localizations.
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Table A2. Univariate Analysis of the Impact of Patient Characteristics Used for Stratiﬁcation on Survival End Points
EFS PFS OS
5-Year EFS %
(95% CI) Median (years) P (log-rank)
5-Year PFS %
(95% CI) Median (years) P (log-rank)
5-Year OS %
(95% CI) Median (years) P (log-rank)
Lymph node involvement .0001 , .0001 .0385
No 63 (56 to 68) n.r. 69 (63 to 75) n.r. 93 (89 to 96) n.r.
Yes 46 (37 to 54) 3.4 51 (42 to 59) 5.6 85 (78 to 90) n.r.
IPI , .0001 , .0001 , .0001
Low to low-intermediate 61 (55 to 66) 9.8 68 (62 to 73) n.r. 93 (90 to 95) n.r.
High-intermediate to high 39 (28 to 49) 2.7 42 (31 to 53) 3.3 78 (67 to 86) n.r.
Primary site .0241 .0013 .0729
Gastric 62 (54 to 69) 5.7 71 (63 to 77) n.r. 93 (88 to 96) n.r.
Extragastric 53 (46 to 59) 10.1 57 (50 to 63) 7.0 88 (83 to 92) n.r.
Prior local therapy* .6200 .5523 .3886
No 57 (51 to 62) 8.7 63 (58 to 68) n.r. 90 (86 to 93) n.r.
Yes 58 (38 to 73) 6.3 62 (41 to 77) 7.0 93 (41 to 77) n.r.
Abbreviations: EFS, event-free survival; IPI, International Prognostic Index; n.r., not reached; OS, overall survival; PFS, progression-free survival.
*Including previous surgery, antibiotic therapy, and/or radiation therapy.
Table A1. Patient Distribution According to Primary Site, Regardless of Stage
Site of Localization
All Patients
(N = 401) Arm A Chlorambucil (n = 131)
Arm B Chlorambucil
Plus Rituximab (n = 132) Arm C Rituximab (n = 138)
Stomach 156 (38.9) 50 (38.2) 49 (37.1) 57 (41.3)
Lung 42 (10.5) 19 (14.5) 10 (7.6) 13 (9.4)
Orbit 38 (9.5) 9 (6.9) 11 (8.3) 18 (13.0)
Salivary glands 25 (6.2) 11 (8.4) 10 (7.6) 4 (2.9)
Skin 23 (5.7) 6 (4.6) 10 (7.6) 7 (5.1)
Upper airways 13 (3.2) 2 (1.5) 6 (4.5) 5 (3.6)
Colon 14 (3.5) 3 (2.3) 7 (5.3) 4 (2.9)
Small bowel 11 (2.7) 2 (1.5) 5 (3.8) 4 (2.9)
Genitourinary tract 5 (1.2) 2 (1.5) 0 (0) 3 (2.2)
Other individual sites* 14 (3.5) 3 (2.3) 7 (5.3) 4 (2.9)
Multiple sites† 60 (15.0) 24 (18.3) 17 (12.9) 19 (13.8)
NOTE. Data are given as No. (%). Differences in site distribution among arms were not statistically signiﬁcant.
*Either gastric or extragastric primary presentation with additional MALT sites involved.
†Including breast, liver, thyroid, bone, soft tissues, pleura, and pancreas, each comprising fewer than ﬁve patients.
Table A3. Cox Models Studying the Effect of Treatment Arm on Survival End Points After Controlling for Stratiﬁcation Factors With a Signiﬁcant Impact on Univariate
Analysis
Event-Free Survival Progression-Free Survival Overall Survival
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Nodal involvement 1.66 (1.24 to 2.22) .001 1.78 (1.29 to 2.45) , .001 1.37 (0.81 to 2.34) .242
High-intermediate to high IPI 1.65 (1.19 to 2.28) .003 1.77 (1.25 to 2.51) .001 3.19 (1.86 to 5.45) , .001
Primary extragastric site 1.24 (0.92 to 1.67) .156 1.50 (1.07 to 2.10) .019 n.a. n.a.
Combination arm 0.53 (0.38 to 0.73) , .001 0.57 (0.41 to 0.82) .002 1.30 (0.77 to 2.20) .329
NOTE. All models included all patients (N = 401) and were statistically signiﬁcant (P . .001).
Abbreviations: HR, hazard ratio; IPI, international prognostic index; n.a., not applicable.
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Table A4. Impact of Patient Characteristics Used for Stratiﬁcation on Complete Remission and Event-Free Survival Rates Across Study Arms
Arm A
Chlorambucil
Arm B
Chlorambucil Plus
Rituximab
Arm C
Rituximab P (univariate analysis)
CR Rate (%)
5-Year EFS
% (95% CI) CR Rate (%)
5-Year EFS
% (95% CI) CR Rate (%)
5-Year EFS
% (95% CI) x2 Test for CR Log-Rank Test for EFS
Lymph node involvement
No 62 54 (43 to 64) 82 73 (62 to 81) 63 61 (50 to 70) .007 .0094
Yes 62 45 (30 to 59) 75 60 (45 to 73) 44 31 (118 to 44) .006 .0054
IPI
Low to low-intermediate 67 57 (47 to 66) 84 74 (64 to 81) 56 52 (42 to 61) , .001 .0005
High-intermediate to high 40 29 (14 to 47) 58 44 (23 to 62) 59 44 (25 to 61) .351 .774
Primary site
Gastric 61 51 (37 to 63) 91 77 (63 to 86) 67 60 (46 to 72) .001 .0018
Extragastric 62 52 (40 to 63) 72 63 (51 to 72) 48 43 (31 to 54) .008 .0218
Abbreviations: CR, complete remission; EFS, event-free survival; IPI, International Prognostic Index.
Table A5. Treatment Outcome According to Stage
End Point
Stage I (n = 170) Stage II and IV (n = 231)
P*% (95% CI) % (95% CI)
CR 75 (67 to 81) 59 (53 to 66) .001
ORR 88 (82 to 93) 84 (79 to 89) .275
In ﬁrst remission at 5 years 85 (77 to 90) 62 (54 to 69) , .0001
5-year EFS 72 (65 to 79) 47 (40 to 53) , .0001
5-year PFS 78 (70 to 84) 52 (45 to 58) , .0001
Abbreviations: CR, complete remission: EFS, event-free survival; ORR, overall response rate; PFS, progression-free survival.
*x2 or log-rank test, as appropriate.
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Table A6. Nonhematologic Adverse Events
Adverse Event
Arm A
Chlorambucil (n = 131)
Arm B
Chlorambucil Plus Rituximab
(n = 132)
Arm C
Rituximab (n = 138)
G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4
Constitutional symptoms
Fatigue 12 4 — — 11 2 — — 12 4 — —
Fever 1 — — — 4 2 — — 5 3 — 1
Sweating — — — — 1 — — — 1 1 — —
GI
Diarrhea 1 1 — — 5 1 — — 3 — — —
Dyspepsia 2 1 — — 2 — 3 — 1 — — —
Nausea 6 1 — — 17 1 — — 6 1 — —
Vomiting — 2 — — — 2 — — — — — —
Dysphagia — — — — — — — 1 — — — —
Anorexia — — — — — — 1 — 1 1 — —
Constipation 2 — — — 2 — — — — — — —
Stomatitis 1 1 — — 3 — — — 1 — — —
Dermatology/skin
Skin rash 5 2 — — 4 2 1 — 3 1 — —
Pruritus/itching 1 1 — — — — 1 — — — — —
Infection
Febrile neutropenia — — — — — — 3 — — — — —
Infection other 3 11 2 1 1 8 4 — 4 6 4 —
Renal/genitourinary
Polyuria 1 — — — — — — — — — — —
Ocular/visual
Tearing, watery eye (epiphora, tearing) — — — — 1 — — — — — — —
Pulmonary/upper respiratory
Dyspnea — — — — — — — — 1 1 — —
Cough 2 — — — — — — — 4 2 — —
Cardiac arrhythmia
Palpitations — — — — 1 — — — — — — —
Atrial ﬁbrillation — — — — — — — 1 — — — —
Cardiac general
Pericardial effusion — — — — 1 — — — — — — —
Hypertension — — — — — 1 — — — — — —
Neurology
Dizziness — — — — 1 — — — 1 — 1 —
Mood alteration, anxiety 1 1 — — — — — — — — — —
Syncope — — 1 — — — — — — — — —
Paresthesia — — — — 1 — — — 2 2 — —
Insomnia 1 — — — 2 1 — — — — — —
Metabolic/laboratory
Transaminase — — 2 1 — 2 — 1 1 — 3 —
Hypophosphatemia — — — — — — 1 — — — — —
GGT — 1 — — — 1 — — — — — —
ALP — — — — 1 — — — — — — —
Hypoalbuminemia — — — — — — — — 1 — — —
Vascular
Hemorrhage 1 — — — 1 — — — 1 — 1 —
Pulmonary embolism (vascular) — — 1 — — — — — — — — —
Auditory/ear
Tinnitus — — — — 1 — — — — — — —
Pain
Arthralgia (pain) — 2 — — — — — — — — — —
Bone/muscle pain — — — — 1 — — — 2 2 — —
Eye pain/blurred vision — — — — — — — — 1 — — —
Gastric pain 6 2 1 — 6 4 1 — 3 4 — —
Headaches 2 — — — 2 2 — — 3 2 — —
Pancreatitis — — — — — — — — — — 1 —
IR symptoms — — — — 15 4 1 1 10 8 2 —
Abbreviations: ALP, alkaline phosphatase; G, toxicity grade (according to Common Terminology Criteria for Adverse Events version 3); GGT, gamma glutamyl
transpeptidase; IR, infusion related (including: bronchospasm, chills, fever, rash, arthralgias, pruritus).
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Table A7. Second-Line Treatment
All Patients Arm A Chlorambucil Arm B Chlorambucil Plus Rituximab Arm C Rituximab
Treatment type*, No. (%) 134 46 36 52
None 14 (10.4) 6 (13.0) 3 (8.3) 5 (9.6)
R alone 10 (7.5) 6 (13.0) 3 (8.3) 1 (1.9)
Alkylating based 12 (8.9) 2 (4.4) 3 (8.3) 7 (13.4)
Purine analog based 5 (3.7) 1 (2.2) 2 (5.6) 2 (3.8)
R-bendamustine 8 (6.0) 1 (2.2) 3 (8.3) 4 (7.7)
R and anthracycline based 16 (12.0) 11 (23.9) 3 (8.3) 2 (3.9)
R and alkylating based 26 (19.4) 7 (15.2) 3 (8.3) 16 (30.8)
Fludarabine/cyclophosphamide-R 2 (1.5) 0 (0.0) 0 (0.0) 2 (3.8)
Others 11 (8.2) 3 (6.5) 4 (11.1) 4 (7.7)
Radiotherapy 15 (11.2) 4 (8.7) 5 (13.9) 6 (11.5)
Unknown 15 (11.2) 5 (10.9) 7 (19.5) 3 (5.8)
Abbreviation: R, rituximab.
*Alkylating-based regimens included single-agent chlorambucil or cyclophosphamide, or cyclophosphamide combined with vincristine and prednisone. Purine
analog–based regimens included single-agent cladribine or ﬂudarabine, or ﬂudarabine combination regimens with cyclophosphamide or with mitoxantrone and
dexamethasone. Anthracycline-based regimens included CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP-like. Other treatments included
antibiotics, everolimus, bortezomib, and radioimmunotherapy with ibritumomab-tiuxetan.
Table A8. Time to Next Therapy*
All
Patients
(n = 83)
Arm A
Chlorambucil
(n = 26)
Arm B Chlorambucil
Plus Rituximab
(n = 23)
Arm C
Rituximab
(n = 34)
Median (years) 2.3 2.7 2.4 1.6
Interquartile
range
(years)
1.3-3.9 1.3-5.3 2.1-4.3 1.0-2.8
*Information on time to next treatment was not included in the follow-up case
report forms of the trial and could only be retrieved for 83 patients. In this small
subset, the difference in the time to next therapy among the three arms was
statistically signiﬁcant (Log-rank test, P 5 .014). These results, however, should
be interpreted with caution due to the considerable amount of missing
information.
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